Liposomal Doxorubicin Market Analysis By Product (J&J [Doxil/Caelyx], Sun Pharma [Lipodox], Teva [Myocet], Others), By Application (Multiple Myeloma, Kaposi Sarcoma, Ovarian, Breast, Kidney Cancer), And Segment Forecasts, 2018 - 2024

Report ID: GVR-1-68038-743-8
Number of Pages: 100
Format: Electronic (PDF)

Historical Range: 2013 - 2015
Industry: Healthcare

Market Segmentation

Liposomal Doxorubicin Product Type Outlook (Revenue, USD Million; 2013 - 2024)
- J&J (Doxil/Caelyx)
- Sun Pharma (Lipodox)
- Teva (Myocet)
- Others
Liposomal Doxorubicin Application Outlook (Revenue, USD Million; 2013 - 2024)
- Leukemia
- Bone Sarcoma
- Breast Cancer
- Endometrial Cancer
- Gastric Cancer
- Liver Cancer
- Kidney Cancer
- Multiple Myeloma
- Ovarian Cancer
- Kaposi Sarcoma
- Other Applications
Liposomal Doxorubicin Regional Outlook (Revenue, USD Million, 2013 - 2024)
- North America
  - The U.S.
    - U.S. Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - U.S. Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications
  - Canada
    - Canada Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - Canada Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications
- Europe
  - UK
    - UK Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - UK Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications
  - Germany
    - Germany Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - Germany Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications
- Asia Pacific
  - Japan
    - Japan Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - Japan Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications
  - China
    - China Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - China Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applicationsl
- Latin America
  - Brazil
    - Brazil Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - Brazil Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications
  - Mexico
    - Mexico Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - Mexico Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications
- MEA
  - South Africa
    - South Africa Product Outlook (Revenue, USD Million, 2013 - 2024)
      - J&J (Doxil/Caelyx)
      - Sun Pharma (Lipodox)
      - Teva (Myocet)
      - Others
    - South Africa Application Outlook (Revenue, USD Million, 2013 - 2024)
      - Leukemia
      - Bone Sarcoma
      - Breast Cancer
      - Endometrial Cancer
      - Gastric Cancer
      - Liver Cancer
      - Kidney Cancer
      - Multiple Myeloma
      - Ovarian Cancer
      - Kaposi Sarcoma
      - Other Applications

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.